Topic: An ECTS paper: Denosumab for the treatment of Rare Bone Disorders in children and adults
Organised by: ECTS Rare bone diseases action group and ERN BOND
Chair: TBD
Speaker: Dr. Oana Bulaicon-Danila, Leids University Medical Center, Netherlands and Dr. Vivian Szymczuk, USA

Date & Time: Thursday, 27 August 2026 from 16.00-17.00hrs CET
Format: Live Interactive Webinar. On-demand recording to be available for ECTS full tier members after the event

Registration

The live webinar is free and open to everyone with an interest in the field.

Register

Agenda:

Introduction (3 min)
Presentation on “Denosumab for the treatment of Rare Bone Disorders in children and adults” by Dr. Bulaicon-Danila and Dr. Szymczuk (40 min)”
Live Q&A from the audience (15 min)
Conclusion and key messages (2 min)

Learning Objectives:

After participating in this session, learners will be able to:

1. Describe the mechanism of action of denosumab and rationale for its use in selected rare bone disorders.
2. Identify clinical and disease-specific factors that influence patient selection, treatment goals, and expected response to denosumab therapy.
3. Recognize the potential benefits, risks, and monitoring requirements associated with denosumab treatment in pediatric and adult patients, including strategies to mitigate complications during treatment initiation and discontinuation.
4. Apply current evidence to develop individualized management approaches for patients with rare bone disorders being considered for denosumab therapy.